We develop early economic model to evaluate cost-effectiveness of a drug while it is still in the initial stages of clinical trials, usually in the pre- or early Phase III stage.
We support pharmaceutical companies and midsize and large consultancies at different steps of an health technology assessment (HTA) submission.
We conduct model adaptations to suit local country requirements based on their local epidemiological, clinical and treatment settings.
We provide independent review of the models developed externally which helps to minimises the risks of technical/formulae errors or methodical errors.
We develop Budget impact models (BIM) to assess the impact on the budget when introducing a new technology or drug.
We conduct systematic literature review (SLR) as well as targeted literature review (TLR) to identify relevant evidence for the decision problem.
We are a boutique consultancy specialising in data analytics, primarily in the domain of Health Economics and Outcomes Research (HEOR), pricing, and market access. Our in-house team of expert health economists and reviewers deliver high-quality work within the stipulated timelines. Generating and communicating key messages effectively lies at the heart of our work culture.
Hemant Rathi and Skyward Analytics have been our partners from the beginning. Our collaboration has been built on a mutual trust and understanding of each other and of our clients needs. Hemant and his team have delivered high quality expertise and deliverables, such as economic models and systematic literature reviews, in a timely and efficient manner. We look forward to our collaboration expanding and delivering for our clients, the best possible HTA solutions
Hemant and his team have done a great job for us. They have been very professional. They have worked closely with our team to meet our deadlines and our customized requirements. We are looking forward to expanding their role with our company.